Search

everythinglearnresearchcommunity

for

Search:↓

TNFα and interleukin-1 blockers reduce skin inflammation from EGFR antibody therapy.

New treatments for skin conditions show promise, especially Coacillium® for hair growth in young people with alopecia areata.

Targeted cancer therapies often cause skin problems that need careful management to improve patient quality of life and treatment success.

Janus kinase inhibitors help some people with severe alopecia areata regrow hair, but not everyone responds, and relapses can happen.

New treatments for advanced skin cancer are improving patient outcomes, but drug resistance and finding the right treatment combinations are still big challenges.

PLAU and SerpinB2 affect cell death differently in various forms of leprosy and could be targets for new treatments.

Tofacitinib was effective in treating hair loss in two patients with alopecia universalis.

JAK inhibitors improve hair growth in alopecia areata, especially in patchy types.

Topical ruxolitinib may help some skin conditions but needs more research for alopecia areata.

Selumetinib causes skin and hair side effects in kids with NF1, affecting treatment and quality of life.

Oral tofacitinib helped regrow hair in over half of the patients with severe alopecia, but relapses and side effects were common.

ARQ-234, a protein designed to treat atopic dermatitis, shows increased effectiveness in early testing.

Tofacitinib helps mice grow more hair by increasing noggin and BMP4 levels, possibly better than minoxidil.

AD198 is more effective than doxorubicin in stopping certain dog cancer cells.

A man with severe hair loss saw hair and nail improvement after 10 months on tofacitinib without side effects.

Oral tofacitinib has a moderate success rate and is generally safe for treating hair loss in some patients.

Tofacitinib effectively treated a woman's severe symptoms from a rare autoimmune condition.

Reducing the dose of Baricitinib to 2mg led to a loss of hair regrowth benefits in nearly half of the patients by Week-104.

High CCL11 levels may indicate poor response to baricitinib in severe alopecia areata.

Biologics and JAK inhibitors may improve treatment for scarring alopecias.

A new treatment using nanoparticles can effectively prevent and reduce hair loss caused by chemotherapy.

Ritlecitinib effectively improves hair regrowth and physician satisfaction in severe alopecia areata over time.

Tofacitinib is a promising treatment for severe alopecia areata, with many patients experiencing complete or partial hair regrowth.

Oclacitinib effectively treated a diabetic cat's severe skin issues without raising glucose levels, and surgery fixed eyelid fusion.

Gefitinib can cause rare scarring hair loss.

Baicalin may help treat severe drug-induced skin reactions.

Erlotinib can cause hair loss and scalp issues, which improve after stopping the drug.

The registry showed that tofacitinib is promising for treating hair loss in children with alopecia areata, but more research is needed.